Literature DB >> 2902403

Treatment of essential thrombocythaemia by alpha 2a interferon.

S Bellucci, J L Harousseau, P Brice, G Tobelem.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2902403     DOI： 10.1016/s0140-6736(88)92625-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  14 in total

1.  Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients.

Authors:  Krisstina Gowin; Prakash Thapaliya; Jan Samuelson; Claire Harrison; Deepti Radia; Bjorn Andreasson; John Mascarenhas; Alessandro Rambaldi; Tiziano Barbui; Catherine J Rea; John Camoriano; Amy Gentry; Jean-Jacques Kiladjian; Casey O'Connell; Ruben Mesa
Journal:  Haematologica       Date:  2012-03-14       Impact factor: 9.941

2.  Recombinant interferon-alpha, but not interferon-gamma is effective therapy for essential thrombocythemia.

Authors:  M J Abegg-Werter; J M Raemaekers; B E de Pauw; C Haanen
Journal:  Blut       Date:  1990-01

3.  Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials.

Authors:  John Mascarenhas; Ruben Mesa; Josef Prchal; Ronald Hoffman
Journal:  Haematologica       Date:  2014-06       Impact factor: 9.941

Review 4.  Contemporary Use of Interferon Therapy in the Myeloproliferative Neoplasms.

Authors:  Charles Elliott Foucar; Brady Lee Stein
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

Review 5.  Primary thrombocythemia: diagnosis, clinical manifestations and management.

Authors:  P J van Genderen; J J Michiels
Journal:  Ann Hematol       Date:  1993-08       Impact factor: 3.673

6.  Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway.

Authors:  Min Lu; Wei Zhang; Yan Li; Dmitriy Berenzon; Xiaoli Wang; Jiapeng Wang; John Mascarenhas; Mingjiang Xu; Ronald Hoffman
Journal:  Exp Hematol       Date:  2010-03-18       Impact factor: 3.084

7.  Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.

Authors:  Ann Mullally; Claudia Bruedigam; Luke Poveromo; Florian H Heidel; Amy Purdon; Therese Vu; Rebecca Austin; Dirk Heckl; Lawrence J Breyfogle; Catherine Paine Kuhn; Demetrios Kalaitzidis; Scott A Armstrong; David A Williams; Geoff R Hill; Benjamin L Ebert; Steven W Lane
Journal:  Blood       Date:  2013-03-13       Impact factor: 22.113

8.  Interferon alpha-2b in the long-term treatment of essential thrombocythemia.

Authors:  S Sacchi; A Tabilio; P Leoni; A Riccardi; A Vecchi; C Messora; F Falzetti; S Rupoli; G Ucci; M F Martelli
Journal:  Ann Hematol       Date:  1991-10       Impact factor: 3.673

Review 9.  Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone.

Authors:  J-J Kiladjian; S Giraudier; B Cassinat
Journal:  Leukemia       Date:  2015-11-25       Impact factor: 11.528

10.  Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosis.

Authors:  Marko Lucijanic; Zdravko Mitrovic; David Cicic; Zeljko Prka; Vlatko Pejsa; Ana Livun; Tajana Stoos-Veic; Zeljko Romic; Marcela Zivkovic; Iva Lucijanic; Zrinka Fabris; Rajko Kusec
Journal:  Int J Hematol       Date:  2017-10-11       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.